Monoklonaalsed antikehad, immuunosupressandid, teised astmavastased ained süsteemseks kasutamiseks, teised dermatoloogilised preparaadid
Contracts total
45 050 000 €
Bids
2
Type
Supplies
Published
14.11.2023
Tender description
Hanke nimetuses toodud ravimite ostmine
Awarded contracts
31.01.2024| Lot | Tenderer | Amount | Bids | Awarded |
|---|---|---|---|---|
| Panitumumab | TAMRO EESTI OÜ | 300 000 € | 2 | 15.01.2024 |
| Gemtuzumabosogamtsiin | MAGNUM MEDICAL OÜ | 100 000 € | 1 | 12.01.2024 |
| Brentuksimabvedotiin | TAMRO EESTI OÜ | 1 000 000 € | 1 | 11.01.2024 |
| Pertuzumab | Roche Eesti Osaühing | 1 000 000 € | 1 | 11.01.2024 |
| Trastuzumabemtansiin | Roche Eesti Osaühing | 4 000 000 € | 1 | 11.01.2024 |
| Obinutuzumab | Roche Eesti Osaühing | 1 000 000 € | 1 | 11.01.2024 |
| Nivolumab | TAMRO EESTI OÜ | 5 000 000 € | 1 | 11.01.2024 |
| Pembrolizumab | MAGNUM MEDICAL OÜ | 11 000 000 € | 1 | 12.01.2024 |
| Blinatumomab | MAGNUM MEDICAL OÜ | 200 000 € | 2 | 16.01.2024 |
| Daratumumab | TAMRO EESTI OÜ | 1 000 000 € | 2 | 15.01.2024 |
| Inotuzumabosogamitsiin | MAGNUM MEDICAL OÜ | 300 000 € | 1 | 12.01.2024 |
| Durvalumab | MAGNUM MEDICAL OÜ | 2 000 000 € | 1 | 12.01.2024 |
| Atezolisumab | Roche Eesti Osaühing | 4 500 000 € | 1 | 11.01.2024 |
| Ipilimumab | TAMRO EESTI OÜ | 1 000 000 € | 1 | 11.01.2024 |
| Karfilsomiib | TAMRO EESTI OÜ | 700 000 € | 2 | 15.01.2024 |
| Iksasomiib | MAGNUM MEDICAL OÜ | 300 000 € | 1 | 12.01.2024 |
| Pertuzumab + trastuzumab | Roche Eesti Osaühing | 5 000 000 € | 1 | 11.01.2024 |
| Küüliku anti-T-lümfotsüütne immuunoglobuliin | MAGNUM MEDICAL OÜ | 100 000 € | 2 | 16.01.2024 |
| Okrelizumab | Roche Eesti Osaühing | 800 000 € | 1 | 11.01.2024 |
| Abatatsept | TAMRO EESTI OÜ | 300 000 € | 1 | 11.01.2024 |
| Fingolimood | MAGNUM MEDICAL OÜ | 50 000 € | 2 | 19.01.2024 |
| Vedolizumab | TAMRO EESTI OÜ | 400 000 € | 1 | 11.01.2024 |
| Golimumab | MAGNUM MEDICAL OÜ | 700 000 € | 2 | 19.01.2024 |
| Anakinra | TAMRO EESTI OÜ | 50 000 € | 2 | 15.01.2024 |
| Ustekinumab | TAMRO EESTI OÜ | 300 000 € | 2 | 15.01.2024 |
| Totsilizumab | TAMRO EESTI OÜ | 400 000 € | 2 | 15.01.2024 |
| Totsilizumab | TAMRO EESTI OÜ | 1 000 000 € | 2 | 15.01.2024 |
| Sarilumab | MAGNUM MEDICAL OÜ | 500 000 € | 2 | 18.01.2024 |
| Guselkumab | MAGNUM MEDICAL OÜ | 50 000 € | 2 | 16.01.2024 |
| Risankizumab | MAGNUM MEDICAL OÜ | 50 000 € | 1 | 12.01.2024 |
| Omalizumab | MAGNUM MEDICAL OÜ | 600 000 € | 2 | 16.01.2024 |
| Mepolizumab | MAGNUM MEDICAL OÜ | 700 000 € | 2 | 16.01.2024 |
| Benralizumab | MAGNUM MEDICAL OÜ | 600 000 € | 1 | 12.01.2024 |
| Eptinezumab | MAGNUM MEDICAL OÜ | 50 000 € | 1 | 12.01.2024 |
Tender lots
37| Lot | Estimated value | Deadline |
|---|---|---|
| Panitumumab | 300 000 € | 18.12.2023 |
| Gemtuzumabosogamtsiin | 100 000 € | 18.12.2023 |
| Brentuksimabvedotiin | 1 000 000 € | 18.12.2023 |
| Pertuzumab | 1 000 000 € | 18.12.2023 |
| Trastuzumabemtansiin | 4 000 000 € | 18.12.2023 |
| Obinutuzumab | 1 000 000 € | 18.12.2023 |
| Nivolumab | 5 000 000 € | 18.12.2023 |
| Pembrolizumab | 11 000 000 € | 18.12.2023 |
| Blinatumomab | 200 000 € | 18.12.2023 |
| Daratumumab | 1 000 000 € | 18.12.2023 |
| Inotuzumabosogamitsiin | 300 000 € | 18.12.2023 |
| Durvalumab | 2 000 000 € | 18.12.2023 |
| Atezolisumab | 4 500 000 € | 18.12.2023 |
| Ipilimumab | 1 000 000 € | 18.12.2023 |
| Karfilsomiib | 700 000 € | 18.12.2023 |
| Iksasomiib | 300 000 € | 18.12.2023 |
| Pertuzumab + trastuzumab | 5 000 000 € | 18.12.2023 |
| Küüliku anti-T-lümfotsüütne immuunoglobuliin | 100 000 € | 18.12.2023 |
| Okrelizumab | 800 000 € | 18.12.2023 |
| Abatatsept | 300 000 € | 18.12.2023 |
| Ekulizumab | 1 000 000 € | 18.12.2023 |
| Fingolimood | 50 000 € | 18.12.2023 |
| Vedolizumab | 400 000 € | 18.12.2023 |
| Golimumab | 700 000 € | 18.12.2023 |
| Anakinra | 50 000 € | 18.12.2023 |
| Ustekinumab | 300 000 € | 18.12.2023 |
| Totsilizumab | 400 000 € | 18.12.2023 |
| Totsilizumab | 1 000 000 € | 18.12.2023 |
| Sarilumab | 500 000 € | 18.12.2023 |
| Guselkumab | 50 000 € | 18.12.2023 |
| Risankizumab | 50 000 € | 18.12.2023 |
| Omalizumab | 600 000 € | 18.12.2023 |
| Mepolizumab | 700 000 € | 18.12.2023 |
| Benralizumab | 600 000 € | 18.12.2023 |
| Dupilumab | 900 000 € | 18.12.2023 |
| Faritsimab | 100 000 € | 18.12.2023 |
| Eptinezumab | 50 000 € | 18.12.2023 |
Similar open tenders
- Parenteraalsed toitelahusedOpen for bidsDeadline 20.10.2026 2 daysEstimated value 400 000 €Published 18.09.2026
- KlesrovimabOpen for bidsDeadline 20.10.2026 2 daysEstimated value 190 000 €Published 05.10.2026
- Puhasruumide desinfektsiooni- ja puhastusvahendidOpen for bidsDeadline 21.10.2026 3 daysPublished 17.09.2026
- Urogenitaalsüsteemi ravimid ja hormoonravimidOpen for bidsDeadline 23.10.2026 5 daysPublished 18.09.2026
- Ravim B01AB05 EnoksapariinOpen for bidsDeadline 27.10.2026 9 daysPublished 21.09.2026
- Kemoteraapias kasutatavad ravimidOpen for bidsDeadline 27.10.2026 9 daysPublished 22.09.2026
Source: Public Procurement Register open data. Amounts exclude VAT. The notice published in the Public Procurement Register is binding.